title: IL2-receptor antagonist (basiliximab) induction therapy is associated with lower morbidity and mortality in renal transplant recipients.
authors.affiliation: Division of Nephrology, Department of Medicine, Queen Mary Hospital, Hong Kong, China. choybyc@hku.hk
authors.forename: B Y
authors.initials: BY
authors.lastname: Choy
authors.forename: T M
authors.initials: TM
authors.lastname: Chan
authors.forename: F K
authors.initials: FK
authors.lastname: Li
authors.forename: S L
authors.initials: SL
authors.lastname: Lui
authors.forename: W K
authors.initials: WK
authors.lastname: Lo
authors.forename: T
authors.initials: T
authors.lastname: Yip
authors.forename: K C
authors.initials: KC
authors.lastname: Tse
authors.forename: K N
authors.initials: KN
authors.lastname: Lai
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology*; D008297:Male; D009017:Morbidity; D011183:Postoperative Complications / Q000145:classification / Q000453:epidemiology / Q000517:prevention & control; D011993:Recombinant Fusion Proteins; D012189:Retrospective Studies
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab